{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:58:57Z","timestamp":1790402337330,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"FDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.antiviral.2014.05.005","type":"journal-article","created":{"date-parts":[[2014,5,10]],"date-time":"2014-05-10T13:47:25Z","timestamp":1399729645000},"page":"36-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains"],"prefix":"10.1016","volume":"108","author":[{"given":"Rama Devudu","family":"Puligedda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Kouiavskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad P.","family":"Adekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7263-4529","authenticated-orcid":false,"given":"Rashmi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandana","family":"Devi Kattala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennady","family":"Rezapkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella","family":"Bidzhieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Dessain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Chumakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.05.005_b0005","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jim.2008.01.015","article-title":"Hybridoma populations enriched for affinity-matured human IgGs yield high-affinity antibodies specific for botulinum neurotoxins","volume":"333","author":"Adekar","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.antiviral.2014.05.005_b0010","doi-asserted-by":"crossref","first-page":"13076","DOI":"10.1128\/JVI.01174-13","article-title":"Highly divergent type 2 and 3 vaccine-derived polioviruses isolated from sewage in Tallinn, Estonia","volume":"87","author":"Al-Hello","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.05.005_b0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1073\/pnas.97.1.73","article-title":"Three-dimensional structure of poliovirus receptor bound to poliovirus","volume":"97","author":"Belnap","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2014.05.005_b0020","first-page":"57","article-title":"Immunological differences between strains of poliomyelitic virus","volume":"12","author":"Burnet","year":"1931","journal-title":"Br. J. Exp. Pathol."},{"key":"10.1016\/j.antiviral.2014.05.005_b0025","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1128\/JVI.02954-12","article-title":"Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria","volume":"87","author":"Burns","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.05.005_b0030","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1128\/JVI.02553-10","article-title":"Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis","volume":"85","author":"Chen","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.05.005_b0040","doi-asserted-by":"crossref","first-page":"20242","DOI":"10.1073\/pnas.1320041110","article-title":"Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor","volume":"110","author":"Chen","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2014.05.005_b0045","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.antiviral.2008.04.002","article-title":"A case for developing antiviral drugs against polio","volume":"79","author":"Collett","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.05.005_b0050","series-title":"Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report","author":"Council","year":"2006"},{"key":"10.1016\/j.antiviral.2014.05.005_b0055","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1743-422X-4-70","article-title":"Epidemics to eradication: the modern history of poliomyelitis","volume":"4","author":"De Jesus","year":"2007","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2014.05.005_b0060","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/rmv.401","article-title":"Polio eradication: the OPV paradox","volume":"13","author":"Dowdle","year":"2003","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2014.05.005_b0065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/525049","article-title":"A large vaccine-derived poliovirus outbreak on Madura Island-Indonesia, 2005","volume":"197","author":"Estivariz","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.05.005_b0070","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.1910.92550480001001i","article-title":"Experimental poliomyelitis in monkeys: active immunization and passive serum protection","volume":"54","author":"Flexner","year":"1910","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2014.05.005_b0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jama.1954.02950010023009","article-title":"Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. 5. Reanalysis of results based on laboratory-confirmed cases","volume":"156","author":"Hammon","year":"1954","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.antiviral.2014.05.005_b0080","doi-asserted-by":"crossref","first-page":"e1002599","DOI":"10.1371\/journal.ppat.1002599","article-title":"Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge","volume":"8","author":"Hird","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2014.05.005_b0085","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1126\/science.1068284","article-title":"Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus","volume":"296","author":"Kew","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2014.05.005_b0090","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"Kew","year":"2005","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2014.05.005_b0095","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1086\/379791","article-title":"Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis","volume":"188","author":"Khetsuriani","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.05.005_b0100","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3851\/IMP1838","article-title":"Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073","volume":"16","author":"Kouiavskaia","year":"2011","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.antiviral.2014.05.005_b0105","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1086\/506359","article-title":"An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China","volume":"194","author":"Liang","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.05.005_b0110","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1128\/AAC.00539-12","article-title":"Characterization of poliovirus variants selected for resistance to the antiviral compound V-073","volume":"56","author":"Liu","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.05.005_b0115","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S0140-6736(04)16150-3","article-title":"Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man","volume":"363","author":"MacLennan","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2014.05.005_b0125","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1086\/587694","article-title":"Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar","volume":"197","author":"Rakoto-Andrianarivelo","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.05.005_b0130","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/0042-6822(88)90251-6","article-title":"Intertypic cross-neutralization of polioviruses by human monoclonal antibodies","volume":"163","author":"Uhlig","year":"1988","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.05.005_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/315684","article-title":"Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion","volume":"182","author":"Valtanen","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.05.005_b0120","series-title":"Report of the Interim Meeting of the Technical Consultation Group on the Global Eradication of Poliovirus","author":"WHO","year":"2002"},{"key":"10.1016\/j.antiviral.2014.05.005_b0140","series-title":"Polio Laboratory Manual","author":"WHO","year":"2004"},{"key":"10.1016\/j.antiviral.2014.05.005_b0145","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1128\/JCM.00712-10","article-title":"Emergence and localized circulation of a vaccine-derived poliovirus in an isolated mountain community in Guangxi, China","volume":"48","author":"Yan","year":"2010","journal-title":"J. Clin. Microbiol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421400134X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421400134X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T02:58:31Z","timestamp":1538621911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421400134X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":28,"alternative-id":["S016635421400134X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.05.005","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}